Bioventix PLC (FRA:51B)

Market Cap	111.62M -43.5%
Revenue (ttm)	15.30M -3.6%
Net Income	8.85M -6.3%
EPS	1.67 -6.3%
Shares Out	n/a
PE Ratio	12.61
Forward PE	13.42
Dividend	1.72 (8.95%)
Ex-Dividend Date	Nov 6, 2025

Volume	n/a
Average Volume	n/a
Open	21.00
Previous Close	21.00
Day's Range	21.00 - 21.00
52-Week Range	18.40 - 37.40
Beta	n/a
RSI	53.46
Earnings Date	Mar 25, 2026

About Bioventix

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 12
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 51B

Financial Performance

In fiscal year 2025, Bioventix's revenue was 13.12 million, a decrease of -3.61% compared to the previous year's 13.61 million. Earnings were 7.58 million, a decrease of -6.33%.

Financial numbers in GBP